TechBio and Time Space

Large Language Models Revolutionizing Drug Discovery

Source

“The real voyage of discovery consists not in seeking new landscapes, but in having new eyes.”
― Marcel Proust

What do time space and AI drug discovery have in common?

If you want to learn more:

Follow IPA Therapeutics, BioStrand and Talem Therapeutics introducing their groundbreaking Universal Foundation AI Model for Multiscale Biological Data Integration.

IPA's CEO, Dr. Jennifer Bath, will participate in the H.C. Wainwright 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference today March 7^th, 2024 (link).

Additionally, the participation of Dirk Van Hyfte MD, PhD, Co-Founder and Head of Innovation of BioStrand at this year's HIMSS®24 conference in Orlando, Florida (alongside their esteemed technology partner, InterSystems), where they will be showcasing the latest advancements in the field of healthcare technology through InterSystems’s Innovator Introduction program (link).

They invite you to join for the lightning pitch session, where they will delve into the capabilities and potential impact of their Universal Foundation AI Model.

Also, they welcome you to engage in fruitful conversations at InterSystem's booth, #1361 at the HIMSS conference, March 12^th-14^th, 2024.

For more:

IPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT Technology.

IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), is an artificial intelligence-driven biotherapeutic research and technology company.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including entities such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”).

The IPA Family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex AI systems to support its proprietary technologies in bioplatform-based antibody discovery. Services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets.

For further information,

visit www.ipatherapeutics.com.